logo-loader

Flying Brands eyeing wider commercialisation options for StoneChecker

Published: 07:28 26 Oct 2017 BST

Medical imaging
The semi-automatic calculation of important clinical information had been received well by clinicians

Flying Brands Limited (LON:FBDU) said prototype testing and evaluation of its StoneChecker kidney stones medical imaging software has been successfully completed.

The company has previously announced that statistical analysis of the product had materially exceeded expectations, and on Thursday it provided further encouraging details from the evaluation process.

READ: Flying Brands says StoneChecker software prototype delivered and early statistical analysis positive

Flying Brands said that the semi-automatic calculation of important clinical information had been well received by clinicians.

“Urologists and radiologists appreciated the easy click process, the display of important clinical information such as stone to skin-surface distance and the map of stone density architecture on CT [computed tomography],” the company said.

The original StoneChecker development plans required the collection of data in order to produce the composite score, but it is now evident that the display of this information in itself is a commercially attractive proposition. There is also a higher level of interest than expected in publishing post-marketing research on the clinical usefulness of the StoneChecker software, the company added.

READ: Flying Brands expects to receive first StoneChecker prototype next month

Other future applications, including non-invasive stone composition assessment (e.g. uric acid vs non-uric acid), have been piloted at Peking Union Medical College Hospital with promising results. This application has potential benefits in assisting in treatment selection and/or dietary recommendations. This new data will be incorporated in future releases of the commercial software.

Meanwhile, there was good news relating to the previously announced delay to the CE (Conformité Européene) mark – the seal that confirms a product meets the essential requirements of the relevant European health, safety and environmental protection legislation – with Flying Brands saying it now expects to obtain CE marking before the end of this year.

IQ-AI advances glioblastoma clinical trial, eyes phase two in 2025

Dr Jennifer Connelly, MD, the Principal Investigator (PI) of the IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) sponsored phase one clinical trial that is being conducted at the Medical College of Wisconsin, joined Proactive's Stephen Gunnion with a positive update from its treatment for recurring...

on 23/2/24